Gene Transfer Technologies Market Size and Share
| Study Period | 2023 - 2030 |
| Market Size (2025) | USD 3.94 Billion |
| Market Size (2030) | USD 6.41 Billion |
| CAGR (2025 - 2030) | 10.20% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Gene Transfer Technologies Market Analysis by Mordor Intelligence
The Gene Transfer Technologies Market size is estimated at USD 3.94 billion in 2025, and is expected to reach USD 6.41 billion by 2030, at a CAGR of 10.20% during the forecast period (2025-2030).
The demand for personalized medicine and advanced therapies is driving growth in the gene transfer technologies market. Customized medicine tailors treatment strategies based on individual genetic profiles, improving patient outcomes, particularly in oncology. Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates this advancement, where gene transfer technologies engineer T-cells using viral or non-viral vectors to express receptors that target and eliminate cancer cells.
The incorporation of genomics and transcriptomics data in treatment planning supports the advancement of precision medicine. In the treatment of non-small-cell lung cancer, the identification of ALK mutations enables the use of targeted therapies, such as crizotinib. Gene transfer technologies are essential in developing and delivering these targeted treatments, specifically in modifying immune cells and enabling gene expression customized to patient genetic profiles. The growth of companion diagnostics, such as Myriad Genetics' BRACAnalysis, helps identify patients who will respond best to specific gene-based therapies. These diagnostics use advanced molecular profiling, increasing the need for efficient and scalable gene delivery tools.
The United States Precision Medicine Initiative and increased regulatory support from the FDA have enhanced investment and innovation in this field. Gene transfer technologies are now used in standalone gene or cell therapies and in combination with other personalized treatment approaches, including CRISPR-based editing and RNA-based therapeutics. The integration of gene transfer tools with advanced therapeutics enables the development of new treatments for cancer, rare genetic disorders, and infectious diseases, supporting continued market growth.
In April 2025, the United States FDA approved Zevaskyn, the first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. Zevaskyn works by inserting healthy COL7A1 genes into patients' skin cells, which are then transplanted back via skin grafts. In March 2024, Novartis launched Scemblix, a gene therapy treatment for Philadelphia chromosome-positive chronic myeloid leukemia. The therapy uses a novel mechanism to target the ABL myristoyl pocket, providing an alternative for patients resistant to existing therapies.
The continuous advancement in gene transfer technologies, coupled with increasing regulatory approvals and successful treatment outcomes, indicates a robust growth trajectory for the market in the coming years. The integration of these technologies with emerging therapeutic approaches suggests sustained innovation and expanded applications across various disease areas. However, the high costs associated with gene delivery technologies, including viral vector production, specialized equipment, and regulatory compliance, pose a significant barrier to market adoption. These elevated expenses particularly hinder access for small research institutions and emerging biotech firms, limiting widespread implementation.
Global Gene Transfer Technologies Market Trends and Insights
The reagents, kits, and assays segment maintain the largest market share in the product segment
The reagents, kits, and assays segment maintains the largest market share in the product segment in the gene transfer technologies market due to its essential role in research and clinical applications. These components enable efficient genetic material delivery into target cells through viral and non-viral methods. The increasing adoption of gene therapy and cell therapy for treating rare genetic disorders, cancers, and infectious diseases has increased the demand for high-quality, ready-to-use transfection kits and reagents. Major companies, including Thermo Fisher Scientific, Takara Bio, Lonza, Promega, and Bio-Rad Laboratories, provide optimized reagents that enhance workflow efficiency, improve transfection rates, and ensure reproducibility in therapeutic development.
The segment's growth is further supported by the advancement of gene editing technologies like CRISPR-Cas9, TALENs, and Zinc Finger Nucleases, which require specific reagents, including guide RNAs, donor DNA templates, and electroporation buffers. Research institutions and biotechnology companies utilize pre-made and custom reagents to accelerate their discovery processes. In 2024, Creative Biolabs introduced an advanced AAV packaging reagent kit for gene therapy research and development, while Polyplus-transfection launched new transfection reagents optimized for CAR-T cell production, addressing the increasing demand from academic laboratories and preclinical developers. The requirement for consistent, regulatory-compliant materials in clinical trials has also increased the demand for GMP-grade reagents and assay kits.
The expansion of diagnostic and companion diagnostic applications, particularly in oncology, has increased the utilization of assay kits that identify genetic mutations associated with treatment responses. Products such as Myriad Genetics' BRAC Analysis, and Qiagen's QIAprep CRISPR kits demonstrate how reagent-based tools facilitate personalized medicine implementation. Increased investment in synthetic biology and vaccine research, including mRNA platforms from companies like Moderna and BioNTech, continues to drive demand for high-performance transfection reagents and vector preparation kits.
With research shifting toward high-throughput and precision-engineered solutions, this segment is projected to maintain its market leadership position. The continuous development of novel gene transfer technologies and increasing applications in cell and gene therapy are expected to further strengthen the dominance of the reagents, kits, and assays segment in the coming years.
North America is expected to dominate the Gene transfer technologies market
North America accounts for a large share of the gene transfer technologies market through its advanced biotech ecosystem, regulatory support, and substantial investment in genetic and cell-based therapies.
The region hosts major companies like Bluebird Bio, CRISPR Therapeutics, Editas Medicine, Spark Therapeutics, and Sangamo Therapeutics, which develop gene and cell therapies using viral and non-viral delivery systems. Research institutions, including Harvard, Stanford, MIT, Johns Hopkins, and the NIH, enhance innovation by connecting lab research with clinical applications, generating consistent demand for gene transfer reagents, kits, and instruments.
The region's supportive regulatory environment reinforces its market leadership. The FDA's approval of Lenmeldy (atidarsagene autotemcel) in March 2024, developed by Orchard Therapeutics for the treatment of metachromatic leukodystrophy (MLD), is a recent example of the growing confidence in gene therapy solutions. Lenmeldy uses ex vivo autologous hematopoietic stem cell gene therapy — a complex procedure made possible through advanced gene transfer technologies. Earlier milestones such as Zolgensma (approved in May 2019) and Abecma (approved in March 2021) paved the way for more innovative therapies, and this continued regulatory support enhances market growth by validating both the safety and effectiveness of gene transfer systems.
Key companies such as Thermo Fisher Scientific, Bio-Techne, Agilent Laboratories, Inc., and Bio-Rad Laboratories, Inc. provide comprehensive gene transfer solutions, from viral vector manufacturing to transfection systems and GMP-grade reagents. Their innovation and production capabilities meet the increasing demands of clinical research and personalized medicine. The combination of robust academic research, active biotech development, and regulatory support establishes North America as the primary growth driver in the global gene transfer technologies market.
The continued expansion of gene therapy applications, coupled with increasing investment in research and development, positions North America to maintain its market leadership in gene transfer technologies for the foreseeable future.
Competitive Landscape
The gene transfer technologies market features intense competition among established biotechnology companies and emerging start-ups. Market participants focus on developing advanced delivery systems, optimizing vectors, and enhancing gene editing tools to maintain competitive advantages. Companies pursue strategic collaborations, product launches, and acquisitions to expand their market presence and improve research capabilities.
The rising demand for cell & gene therapies, coupled with expanding clinical applications across oncology, rare diseases, and genetic disorders, intensifies market competition. Market participants enhance their offerings through improvements in electroporation, viral and non-viral vector development, and automated delivery systems to provide efficient and targeted gene transfer solutions. The rising research on personalized medicine and precision therapies continues to drive technological advancement and market competition.
Key international players—including Thermo Fisher Scientific, Lonza Group, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck KGaA, and MaxCyte Inc.
Gene Transfer Technologies Industry Leaders
-
Thermo Fisher Scientific, Inc.
-
Danaher Corporation
-
Merck KGaA
-
Agilent Technologies, Inc.
-
Bio-Rad Laboratories. Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- September 2024: Cytiva introduced a new RNA delivery LNP kit compatible with its NanoAssemblr Ignite and Ignite+ systems. This launch expands the GenVox-ILM product line, aiming to accelerate the development of mRNA and siRNA-based vaccines, thereby supporting advancements in RNA therapeutics.
- September 2024: MaxCyte entered into a strategic platform license (SPL) agreement with Kamau Therapeutic. Through this agreement, Kamau secured non-exclusive rights—covering research, clinical, and commercial use—to access MaxCyte’s Flow Electroporation technology and EXPERT platform. This collaboration will support Kamau’s work on homology-directed repair (HDR)-based novel gene correction therapies.
Global Gene Transfer Technologies Market Report Scope
The Gene Transfer Technologies Market refers to the global ecosystem of tools, methods, and products involved in the introduction of genetic material (DNA or RNA) into cells to modify their function or correct genetic defects. These technologies are fundamental to gene therapy, cell therapy, genetic engineering, and biomedical research, and are central to the development of personalized medicine and regenerative treatments.
The Gene Transfer Technologies Market is segmented into product type, mode, method, application, and geography. By product, the market is segmented into reagents, kits & assays, consumables, instruments, and other products. By mode, the market is segmented into viral vectors, non-viral vectors, and physical methods. By method, the market is segmented into in vivo, ex vivo, and in vitro. By application, the market is segmented into therapeutic and research. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America. The report also provides market size and forecasts for 17 countries across these regions, with revenue (USD) serving as the basis for projections in each segment.
| By Product | Reagents, Kits, and Assays | ||
| Consumables | |||
| Instruments | |||
| Other Products | |||
| By Mode | Viral Vectors | Retrovirus | |
| Adenovirus | |||
| Adeno-Associated Virus | |||
| Other viral vectors | |||
| Non Viral Vectors | Chemical Methods | ||
| Liposome Mediated | |||
| Calcium Phosphate | |||
| DEAE-Dextran | |||
| Cationic Polymers | |||
| Other chemical methods | |||
| Physical Methods | Electroporation | ||
| Microinjection | |||
| Gene guns | |||
| Other physical methods | |||
| By Method | In Vivo | ||
| Ex Vivo | |||
| In Vitro | |||
| By Application | Therapeutic Application | Gene Therapy | |
| Cell Therapy | |||
| Vaccines | |||
| Others | |||
| Research Applications | Drug Discovery & Development | ||
| Infectious Diseases | |||
| Genetic & Neurological Disorders | |||
| Autoimmune Diseases | |||
| Others | |||
| By End User | Pharmaceutical & Biotechnology Companies | ||
| Academic & Research Institutes | |||
| Other end users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Reagents, Kits, and Assays |
| Consumables |
| Instruments |
| Other Products |
| Viral Vectors | Retrovirus |
| Adenovirus | |
| Adeno-Associated Virus | |
| Other viral vectors | |
| Non Viral Vectors | Chemical Methods |
| Liposome Mediated | |
| Calcium Phosphate | |
| DEAE-Dextran | |
| Cationic Polymers | |
| Other chemical methods | |
| Physical Methods | Electroporation |
| Microinjection | |
| Gene guns | |
| Other physical methods |
| In Vivo |
| Ex Vivo |
| In Vitro |
| Therapeutic Application | Gene Therapy |
| Cell Therapy | |
| Vaccines | |
| Others | |
| Research Applications | Drug Discovery & Development |
| Infectious Diseases | |
| Genetic & Neurological Disorders | |
| Autoimmune Diseases | |
| Others |
| Pharmaceutical & Biotechnology Companies |
| Academic & Research Institutes |
| Other end users |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Key Questions Answered in the Report
How big is the Gene Transfer Technologies Market?
The Gene Transfer Technologies Market size is expected to reach USD 3.94 billion in 2025 and grow at a CAGR of 10.20% to reach USD 6.41 billion by 2030.
What is the current Gene Transfer Technologies Market size?
In 2025, the Gene Transfer Technologies Market size is expected to reach USD 3.94 billion.
Who are the key players in Gene Transfer Technologies Market?
Thermo Fisher Scientific, Inc., Danaher Corporation, Merck KGaA, Agilent Technologies, Inc. and Bio-Rad Laboratories. Inc. are the major companies operating in the Gene Transfer Technologies Market.
Which is the fastest growing region in Gene Transfer Technologies Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Gene Transfer Technologies Market?
In 2025, the North America accounts for the largest market share in Gene Transfer Technologies Market.
What years does this Gene Transfer Technologies Market cover, and what was the market size in 2024?
In 2024, the Gene Transfer Technologies Market size was estimated at USD 3.54 billion. The report covers the Gene Transfer Technologies Market historical market size for years: 2023 and 2024. The report also forecasts the Gene Transfer Technologies Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Gene Transfer Technologies Industry Report
Statistics for the 2025 Gene Transfer Technologies market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gene Transfer Technologies analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
